PROTOKINETIX BLOG

Find out how AAGP® is changing lives through cell survival

As we move forward with clinical research for our anti-aging glycopeptide, AAGP®, we continue to uncover new areas of opportunity for the molecule. See how AAGP® is helping to provide more hope for patients and investors in the areas of ophthalmology, transplants, dermatology and biomanufacturing.

May 09, 2019

byncaipen

Transplants

Agreement Secured by ProtoKinetix to Start Heart Research Product Validation Studies

Marietta, Ohio ProtoKinetix, Incorporated (www.protokinetix.com) (the “Company” or “ProtoKinetix”) (OTCQB:PKTX) is announcing that the Company has secured a partnership agreement with IMPART investigator team Canada at Dalhousie University and has...Read more

Feb 26, 2019

byncaipen

Transplants

ProtoKinetix Releases Third in a Series of Scientific Update Videos

Marietta, Ohio ProtoKinetix, Incorporated (www.protokinetix.com) (the “Company” or “ProtoKinetix”) (OTCQB:PKTX) announces the launch of the third in a series of informational videos by the Principal Investigators in each field currently...Read more

Request More Information

Talk to a member of the ProtoKinetix team to learn more about our research and results.